Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators-Reference-Cited by-同舟云学术

Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators

Published:2021-10-21 Issue:10 Volume:7 Page:e213428
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Fan Ying¹,Sun Tao²,Shao Zhimin³,Zhang Qingyuan⁴,Ouyang Quchang⁵,Tong Zhongsheng⁶,Wang Shusen⁷,Luo Yang¹,Teng Yuee⁸,Wang Xiaojia⁹,Wang Shu¹⁰,Liu Qiang¹¹,Feng Jifeng¹²,Shen Kunwei¹³,Song Yanqiu¹⁴,Wang Jiayu¹,Ma Fei¹,Li Qing¹,Zhang Pin¹,Xu Binghe¹

Affiliation:

1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

2. Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang, China

3. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

4. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China

5. Department of Breast Oncology, Hunan Cancer Hospital, Changsha, China

6. Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

7. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

8. Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China

9. Department of Breast Oncology, Zhejiang Cancer Hospital, Hangzhou, China

10. Department of Breast Surgery, Peking University People’s Hospital, Beijing, China

11. Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

12. Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, China

13. Department of Breast Oncology, Ruijin Hospital of Shanghai Jiaotong University, Shanghai, China

14. Department of Breast Oncology, The First Hospital of Jilin University, Changchun, China

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2783528/jamaoncology_fan_2021_oi_210050_1634002247.13217.pdf

Reference31 articles.

1. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer.;Baselga;N Engl J Med,2012

2. Everolimus plus exemestane for hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer: overall survival results from BOLERO-2.;Piccart;Ann Oncol,2014

3. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from BOLERO-2.;Hortobagyi;J Clin Oncol,2016

4. Cyclin-dependent kinase pathways as targets for cancer treatment.;Shapiro;J Clin Oncol,2006

5. Palbociclib and letrozole in advanced breast cancer.;Finn;N Engl J Med,2016

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer;Cancer Research;2024-05-15

3. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer;Breast Cancer;2024-04-17

4. PHD Finger Protein 1 (PHF1) as a Novel Marker Regulates Progression of Colon Cancer through Cell Cycle Pathway and Contributes to Immunotherapy;J BIOL REG HOMEOS AG;2024

5. Immune checkpoints between epithelial-mesenchymal transition and autophagy: A conflicting triangle;Cancer Letters;2024-03